Vimarsana
Biggest News Aggregation in the World

Page 7 - Daptorum Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daptorum Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daptorum Group Today - Breaking & Trending Today

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group - Vimarsana News

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

Regulatory News: Aptorum Group Limited , today announced that it entered into a non-binding Letter of Intent and Term Sheet for the acquisition of 100% of URF Holding Group Limited and its... | March 27, 2023

Aptorum Group Inks Non-binding LoI And Term Sheet To Buy 100% Of URF Holding Group - Vimarsana News

Aptorum Group Inks Non-binding LoI And Term Sheet To Buy 100% Of URF Holding Group

Aptorum Group Ltd. (APM) announced Monday that it entered into a non-binding Letter of Intent and Term Sheet for the acquisition of 100% of URF Holding Group Ltd.

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report - Vimarsana News

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report

ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Money

Aptorum Group Limited: Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma - Vimarsana News

Aptorum Group Limited: Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1

Aptorum Group Limited: Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus - Vimarsana News

Aptorum Group Limited: Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions